Abstracts tagged "Antiphospholipid antibodies"

Abstract Number: 1664 • 2014 ACR/ARHP Annual Meeting
Novel Risk Factors for Systemic Lupus Erythematosus (SLE) Flares in Patients with End-Stage Renal Disease: Is SLE in Patients with End-Stage Renal Disease a “sleeping beauty”?
Jorge Alcocer-Varela¹, Mariana Quintanar², Javier Merayo-Chalico³, Ana Barrera-Vargas¹ and Diana Gómez-Martín¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose Renal involvement in systemic lupus erythematosus (SLE) is frequent, and a high percentage of patients (~15%) develop end-stage renal disease (ESRD) even with optimal…
Abstract Number: 1342 • 2014 ACR/ARHP Annual Meeting
Improving Serologic Testing for Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus
Arshad Mustafa¹, Kara Prescott², Una Makris³ and E. Blair Solow⁴, ¹Internal Medicine - Rheumatology, UT Southwestern Medical Center at Dallas, Dallas, TX, ²Internal Med - Rheumatology, Dallas VA Medical Ctr, Dallas, TX, ³Rheumatology, Dallas VA Medical Ctr, Dallas, TX, ⁴Internal Medicine, Division of Rheumatic Diseases, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Antiphospholipid antibodies (APL) in patients with Systemic Lupus Erythematosus (SLE) are common. Persistent positivity is known to increase the risk of thrombosis and pregnancy…
Abstract Number: 691 • 2014 ACR/ARHP Annual Meeting
Prevalence of Subclinical Echocardiographic Abnormalities in Patients with Systemic Lupus Erythematosus (SLE)
Sergi Heredia¹, Javier Narváez², Andrea Zacarias¹, Eulalia Armengol¹, Gloria Albert¹, Alex Roset³, Patricia Siguenza³, Xavier Juanola⁴, Manel Rubio Rivas³ and Joan Miquel Nolla¹, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ³Internal Medicine, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Rheumatology, University Hospital Bellvitge, Barcelona, Spain
Background/Purpose: To determine the prevalence of unsuspected echocardiographic abnormalities (excluding pericardial effusion) and to identify associated clinical and laboratory features in a large SLE cohort.…
Abstract Number: 15 • 2014 ACR/ARHP Annual Meeting
Performance of an Automated Chemiluminescence Assay for Anti-Cardiolipin and Anti-Beta2glycoprotein I Antibodies Detection in a Cohort of 400 Clinically Characterized Consecutive Routine Samples
Alessandra Zanola¹, Laura Andreoli¹, Cecilia Nalli¹, Flavio Allegri¹, Michael Mahler², Gary Norman³ and Angela Tincani¹, ¹Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ²Research, INOVA Diagnostics, San Diego, CA, ³INOVA Diagnostics, San Diego, CA
Background/Purpose: Several immunoassays are available for the detection of anti-cardiolipin (aCL) and anti-beta2glycoprotein I antibodies (anti-B2GPI), but standardization and harmonization of these tests is an…
Abstract Number: 10 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Antibodies and Neuropsychiatric Events in Pediatric Patients
Mileka Gilbert¹ and Lenore M. Buckley², ¹Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, ²Section of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: An association between anti-phospholipid antibodies (aPL abs) and non-thrombotic neuropsychiatric events has been reported in pediatric and adult patients, including patients who do not…
Abstract Number: 5 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid-Associated Nephropathy Is a Risk for Developing Arterial Thromboses in Patients with Systemic Lupus Erythematosus
Tomoko Fukui, Shinsuke Yasuda, Toshiyuki Watanabe, Kazumasa Ohmura, Sanae Shimamura, Ikuma Nakagawa, Atsushi Noguchi, Haruki Shida, Yuka Shimizu, Michihito Kono, Takashi Kurita, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Antiphospholipid-associated nephropathy (APLN) is characterized by coexistence of antiphospholipid antibodies (aPLs) and renal small-vessel vasculopathy/chronic renal ischemia. Consequences of APLN to thrombosis have yet…
Abstract Number: 10 • 2013 ACR/ARHP Annual Meeting
Autoantibodies Targeting Domain 1 Of Beta 2 Glycoprotein I As Promising Marker In The Diagnosis and Risk Stratification Of The Antiphospholipid Syndrome
Navid Zohoury¹, Munther A. Khamashta², Tatsuya Atsumi³, Jacek Musial⁴, Toshiyuki Watanabe⁵, Maria Papp⁶, Concepción González-Rodríguez⁷, Roger Albesa¹, Gary L. Norman¹, Pier-Luigi Meroni⁸ and Michael Mahler¹, ¹Research, INOVA Diagnostics, San Diego, CA, ²Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ³Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁴Depment of Medicine, Jagiellonian University Medical College, Krakow, Poland, ⁵Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan, ⁶MHSCInstitute of Medicine, Department of Gastroenterology, University of Debrecen, Debrecen, Hungary, ⁷University Hospital Virgen Macarena, Sevilla, Spain, ⁸Int Medicine, University of Milan, Milano, Italy
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by the presence of antibodies to phospholipids (aPL) and to β2glycoprotein I (β2GPI) in patients with thrombosis or pregnancy…
Abstract Number: 14 • 2013 ACR/ARHP Annual Meeting
Isotype Dependent Performance Of Beta₂glycoprotein I Immunoassays In Two Diverse Patient Cohorts: Implications For Assay Harmonization and Standardization
Anne E. Tebo^1,2, Rohan Willis³, Troy Jaskowski⁴, Jane E. Salmon⁵, Michelle Petri⁶, Ware D. Branch^7,8 and Silvia S. Pierangeli³, ¹Pathology, University of Utah, Salt Lake City, UT, ²Medical Directorship, ARUP Laboratories, Salt Lake City, UT, ³Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ⁴ARUP Laboratories, Salt Lake City, UT, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Obsterics and Gynecology, Univ of Utah, Salt Lake City, UT, ⁸Intermountain Healthcare, Salt Lake City, UT
Background/Purpose: The presence IgG and/or IgM beta2 glycoprotein I (β2GPI) antibodies are associated with thrombosis and/or pregnancy-related morbidity in antiphospholipid syndrome (APS) and/or systemic lupus…
Abstract Number: 18 • 2013 ACR/ARHP Annual Meeting
Clinical Correlates Of Positive Anti-Cardiolipin and β-2 Glycoprotein 1 Antibodies In a Cohort Of 110 Patients At Mayo Clinic
Uma Thanarajasingam¹, Cynthia S. Crowson², Melissa R. Snyder³, Rajeev Pruthi⁴, Harvinder S. Luthra⁵ and Kevin G. Moder⁶, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³2Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ⁴Divison of Hematology, Mayo Clinic, Rochester, MN, ⁵Medicine/Division of Rheum, Mayo Clinic, Rochester, MN, ⁶Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Testing for antiphospholipid antibodies is typically indicated for diagnosis and prognosis of antiphospholipid syndromes, however, selected patients undergo testing for other reasons. The clinical…
Abstract Number: 2651 • 2013 ACR/ARHP Annual Meeting
The Association Between Antiphospolipid Antibodies and Related Clinical Outcomes: A Critical Review Of The Literature
Cecilia B. Chighizola¹, Laura Andreoli², Alessandra Banzato³, Guilherme Ramires de Jesus⁴, Guillermo J. Pons-Estel⁵, Doruk Erkan⁶ and On Behalf of APS Action⁷, ¹Rheumatology, Istituto Auxologico Italiano, University of Milan, Cusano Milanino, Italy, ²Rheumatology Unit, University of Brescia, Brescia, Italy, ³Department of Cardiac Thoracic and Vascular Sciences, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy, ⁴Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁵Servicio de Enfermedades Autoinmunes, Department of Autoimmune Diseases, Institut Clìnic de Medicina i Dermatologia, Hospital Clìnic, Barcelona, Spain, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷APS ACTION, New York, NY
Background/Purpose: AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION) is an international network that has been created to design and conduct APS…
Abstract Number: 2654 • 2013 ACR/ARHP Annual Meeting
IgG Antibodies Directed Against Domain I Of ß₂-Glycoprotein I Are Significant Predictors Of Thromboembolic Events In Patients With Antiphospholipid Antibodies. A Prospective Cohort Study
Stephane Zuily¹, Bas de Laat², Francis Guillemin³, Pierre Kaminsky⁴, Hilde Kelchtermans⁵, Roger Albesa⁶, Gary L. Norman⁶, Anne-Christine Rat⁷, Philip de Groot⁸, Thomas Lecompte⁹, Veronique Regnault¹⁰ and Denis Wahl¹, ¹CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France, ²Biochemistry, CARIM, Maastricht University, The Netherlands; Clinical Chemistry and Hematology, UMC Utrecht, The Netherlands; Synapse BV, Maastricht, The Netherlands; Sanquin Research, Amsterdam, The Netherlands, Maastricht, Netherlands, ³CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁴Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Orphan disease unit, Nancy, F-54000, France;, Nancy, France, ⁵Biochemistry, CARIM, Maastricht University, The Netherlands; Synapse BV, Maastricht, The Netherlands, Maastricht, Netherlands, ⁶Research, INOVA Diagnostics, San Diego, CA, ⁷Université de Lorraine, Nancy, F-54000, France; Inserm, CIC-EC CIE6, Nancy, F-54000, France; CHU de Nancy, Clinical Epidemiology and Evaluation Department, Nancy, F-54000, France; CHU de Nancy, Rheumatology department, Nancy, France, ⁸Clinical Chemistry and Hematology, UMC Utrecht, The Netherlands, Utrecht, Netherlands, ⁹Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Haematology Laboratory, Nancy, F-54000, France; Division of Haematology, HUG, Geneva, Switzerland (current address), Geneva, Switzerland, ¹⁰Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Contrat d’interface, Nancy, F-54000, France, Nancy, France
AbstractBackground/Purpose : Our objective was to prospectively determine the prognostic significance of laboratory variables regarding thrombotic events during follow-up, including novel assays IgG antibodies directed…
Abstract Number: 556 • 2013 ACR/ARHP Annual Meeting
Depletion Of The Gut Microbiota Prevents β₂-Glycoprotein I Antibody Production and Mortality In a Model Of Antiphospholipid Syndrome
Silvio M. Vieira¹, Andrew Yu¹, Odelya E. Pagovich¹, Eleni Tiniakou², John Sterpka¹ and Martin A. Kriegel^3,4, ¹Yale School of Medicine, New Haven, CT, ²Yale University School of Medicine, New Haven, CT, ³Immunobiology, Yale School of Medicine, New Haven, CT, ⁴Medicine/Division of Rheumatology, Yale School of Medicine, New Haven, CT
Background/Purpose: Infectious triggers have been implicated in transient antiphospholipid antibody production in both mice and humans. The cause of persistent anti-β2-glycoprotein I (β2GPI) antibody production…
Abstract Number: 19 • 2013 ACR/ARHP Annual Meeting
Association Of Antiphospholipid Antibodied Detected In The Aphl ELISA With Clinical Manifestations Of The Antiphospholipid Syndrome In Two Lupus Cohorts
Silvia S. Pierangeli¹, Rohan Willis², Michelle Petri³, Hong Fang⁴, Monica Smikle⁵, Karel de Ceulaer⁶ and E. Nigel Harris⁷, ¹Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ²Int Medicine/Rheumatology, University of Texas Medical Branch, Galveston, TX, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Microbiology, University of the West Indies, Kgn 7, Jamaica, ⁶Microbiology, University of the West Indies, KIngston, Jamaica, ⁷Office of the Vice Chancellor, The University of the West Ind, Kingston, Jamaica
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by the presence of antibodies to phospholipid (aPL) and to β2glycoprotein I (β2GPI) in patients with thrombosis or pregnancy…
Abstract Number: 3 • 2013 ACR/ARHP Annual Meeting
The Global Antiphospholipid Syndrome Score (GAPSS) In Primary APS
Savino Sciascia¹, Giovanni Sanna², Veronica Murru³, Dario Roccatello¹, Munther A. Khamashta⁴ and Maria Laura Bertolaccini³, ¹Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ²Louise Coote Lupus Unit, St. Thomas' Hospital, London, United Kingdom, ³Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ⁴Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom
Background/Purpose: Antiphospholipid Syndrome (APS) is a heterogeneous entity with a wide variation in clinical course and laboratory profile. We aimed to evaluate the clinical utility…
Abstract Number: 4 • 2013 ACR/ARHP Annual Meeting
Proteomic Analyses Of Monocyte Responses To IgG From Patients With Antiphospholipid Syndrome
Vera M. Ripoll¹, Anastasia Lambrianides², Wendy Heywood³, Anisur Rahman⁴, Yiannis Ioannou⁵ and Ian Giles⁶, ¹Centre for Rheumatology, Rayne Institute, 4th floor, Centre for Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology Research, University College London, London, United Kingdom, ³Institute of Child Health, University College London, London, United Kingdom, ⁴Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ⁵Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁶Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disorder characterised by recurrent vascular thrombosis (VT) and/or pregnancy morbidity (PM) caused by antiphospholipid antibodies (aPL). Whilst aPL are known…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.